Skip to main content

Table 2 Initial empiric antibiotic therapy in modified intention-to-treat patients grouped as defined per bacteriologic documentation (visit 2)

From: Empiric broad-spectrum antibiotic therapy of nosocomial pneumonia in the intensive care unit: a prospective observational study

 

Group I (n = 113, 46.3%)

Group II (n = 14, 5.7%)

Group III (n = 38, 15.6%)

Group IV (n = 56, 23.0%)

Group V (n = 23, 9.4%)

Overall (n = 244, 100%)

Chi-square P value

Dose of imipenem (%)

      

0.51

   <3 g/day

19.5

-

10.5

9.0

17.3

14.3

 

   3 g/day

62.8

85.7

73.7

60.7

65.2

65.6

 

   >3 g/day

17.7

14.3

15.8

30.4

17.4

20.1

 

Empiric regimen (%)

      

0.64

   Imipenem only

19.5

7.1

18.4

21.4

8.7

18.0

 

   Imipenem + aminoglycoside

37.2

50.0

42.2

48.2

34.8

41.0

 

Amikacin

24.8

28.6

21.1

41.1

26.1

28.3

 

Tobramycin

12.4

21.4

21.1

7.1

8.7

12.7

 

   Imipenem + glycopeptide

15.0

21.4

21.1

8.9

21.7

15.6

 

Vancomycin

9.7

21.4

13.2

8.9

13.0

11.1

 

Teicoplanin

5.3

-

7.9

-

8.7

4.5

 

   Imipenem + aminoglycoside + glycopeptide

28.3

21.4

18.4

21.4

34.8

25.4

 
  1. Group I, patients with an unknown aetiology and unmodified therapy; Group II, patients with resistant organisms, who had unmodified therapy; Group III, patients with susceptible organisms, who had unmodified therapy; Group IV, patients who had susceptible organisms and whose therapy was modified accordingly; and, Group V, patients who initially received inadequate antibiotic therapy, which was later modified on the basis of cultures.